Next-Generation Biomanufacturing Market by Type, Application, End-User

Description

List of Tables

[191 Pages Report] The Next-Generation Biomanufacturing Market size was estimated at USD 19.10 billion in 2023 and expected to reach USD 20.69 billion in 2024, at a CAGR 9.02% to reach USD 34.97 billion by 2030.

Global Next-Generation Biomanufacturing Market

KEY MARKET STATISTICS
Base Year [2023]	USD 19.10 billion
Estimated Year [2024]	USD 20.69 billion
Forecast Year [2030]	USD 34.97 billion
CAGR (%)	9.02%

Next-Generation Biomanufacturing Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Next-Generation Biomanufacturing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Next-Generation Biomanufacturing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Next-Generation Biomanufacturing Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., Applikon Biotechnology BV, bbi-biotech GmbH, Biofluidica, Inc., Danaher Corporation, Eppendorf AG, ESCO Group, Eurofins Scientific SE, GEA Group AG, GENEWIZ, Inc. by Azenta Life Sciences, Hamilton Company, Illumina, Inc., Macrogen Inc., Merck KGaA, Oxford Nanopore Technologies plc, PBS Biotech, Inc., PerkinElmer Inc., QIAGEN N.V., Sartorius AG, Shanghai Bailun Biotechnology Co., Ltd., Solaris Biotechnology Srl by DONALDSON ITALIA S.R.L., Takara Bio Inc., Thermo Fisher Scientific Inc., ZETA GmbH, and Zymo Research Corporation.

Market Segmentation & Coverage

This research report categorizes the Next-Generation Biomanufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Continuous Upstream Biomanufacturing
- Downstream Biomanufacturing
- Single-Use Upstream Biomanufacturing
Application
- Hormones
- Monoclonal Antibodies
- Recombinant Proteins
- Vaccines
End-User
- Biopharmaceutical Companies
- Contract Manufacturing Organizations
- Research Institutions
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Next-Generation Biomanufacturing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Next-Generation Biomanufacturing Market?

3. What are the technology trends and regulatory frameworks in the Next-Generation Biomanufacturing Market?

4. What is the market share of the leading vendors in the Next-Generation Biomanufacturing Market?

5. Which modes and strategic moves are suitable for entering the Next-Generation Biomanufacturing Market?

Product Code: MRR-5C6F41F5B006

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Next-Generation Biomanufacturing Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Growing demand for biopharmaceuticals and gene therapies
  - 5.1.1.2. Rising need to enhance flexibility and scalability of biomanufacturing
  - 5.1.1.3. Adoption of process automation and continuous manufacturing
- 5.1.2. Restraints
  - 5.1.2.1. High cost of next-generation biomanufacturing
- 5.1.3. Opportunities
  - 5.1.3.1. Advancements in next-generation biomanufacturing
  - 5.1.3.2. Significant investments in next-generation biomanufacturing
- 5.1.4. Challenges
  - 5.1.4.1. Technical challenges in next-generation biomanufacturing
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Next-Generation Biomanufacturing Market, by Type

6.1. Introduction
6.2. Continuous Upstream Biomanufacturing
6.3. Downstream Biomanufacturing
6.4. Single-Use Upstream Biomanufacturing

7. Next-Generation Biomanufacturing Market, by Application

7.1. Introduction
7.2. Hormones
7.3. Monoclonal Antibodies
7.4. Recombinant Proteins
7.5. Vaccines

8. Next-Generation Biomanufacturing Market, by End-User

8.1. Introduction
8.2. Biopharmaceutical Companies
8.3. Contract Manufacturing Organizations
8.4. Research Institutions

9. Americas Next-Generation Biomanufacturing Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Next-Generation Biomanufacturing Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Next-Generation Biomanufacturing Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
- 13.1.1. Agilent Technologies, Inc.
- 13.1.2. Applikon Biotechnology BV
- 13.1.3. bbi-biotech GmbH
- 13.1.4. Biofluidica, Inc.
- 13.1.5. Danaher Corporation
- 13.1.6. Eppendorf AG
- 13.1.7. ESCO Group
- 13.1.8. Eurofins Scientific SE
- 13.1.9. GEA Group AG
- 13.1.10. GENEWIZ, Inc. by Azenta Life Sciences
- 13.1.11. Hamilton Company
- 13.1.12. Illumina, Inc.
- 13.1.13. Macrogen Inc.
- 13.1.14. Merck KGaA
- 13.1.15. Oxford Nanopore Technologies plc
- 13.1.16. PBS Biotech, Inc.
- 13.1.17. PerkinElmer Inc.
- 13.1.18. QIAGEN N.V.
- 13.1.19. Sartorius AG
- 13.1.20. Shanghai Bailun Biotechnology Co., Ltd.
- 13.1.21. Solaris Biotechnology Srl by DONALDSON ITALIA S.R.L.
- 13.1.22. Takara Bio Inc.
- 13.1.23. Thermo Fisher Scientific Inc.
- 13.1.24. ZETA GmbH
- 13.1.25. Zymo Research Corporation
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing